BioCentury
ARTICLE | Clinical News

ADC Therapeutics discontinues HER2 program

April 25, 2018 6:51 PM UTC

ADC Therapeutics S.A. (Épalinges, Switzerland) said it discontinued ADCT-502 after Phase I data of the antibody-drug conjugate (ADC) in patients with HER2-expressing advanced solid tumors did not show "sufficient patient benefit to justify further development."

ADCT-502 comprises an engineered version of trastuzumab, which is a humanized mAb against HER2, and a pyrrolobenzodiazepine (PBD) dimer toxin. The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) markets Herceptin trastuzumab to treat HER2-positive cancers...